


Facial Nerve Sacrifice During Parotidectomy for Metastatic Cutaneous Squamous Cell Carcinoma

Jessica Yesensky, MD¹, Roberto N. Solis, MD², and Arnaud Bewley, MD²

OTO Open
 2021, Vol. 5(1) 1–5
 © The Authors 2021
 Article reuse guidelines:
sagepub.com/journals-permissions
 DOI: 10.1177/2473974X21996627
<http://oto-open.org>


Abstract

Objective. We analyzed the incidence of facial nerve sacrifice during parotidectomy for metastatic cutaneous squamous cell carcinoma (CSCC).

Study Design. We retrospectively reviewed the charts of patients with cutaneous squamous cell carcinoma.

Setting. We used our CSCC institutional database, which includes patients treated at the University of California–Davis from 2001 to 2018.

Methods. We evaluated patients who presented with biopsy-proven head and neck CSCC who underwent parotidectomy as a part of surgical treatment. We assessed the frequency of facial nerve sacrifice required in patients with normal preoperative facial nerve function with metastatic disease to the parotid. We evaluated the association between sacrifice and high-risk tumor variables using multivariate analysis.

Results. We identified 53 patients with parotid metastasis and normal preoperative facial nerve function. Thirteen percent of patients required sacrifice of the main trunk of the facial nerve and 27% required sacrifice of a branch of the facial nerve. All patients who underwent facial nerve sacrifice had extracapsular spread (ECS). Perineural invasion (PNI) in the primary tumor (odds ratio [OR], 9.11; $P = .041$) and location of metastasis within the parotid body (OR, 6.6; $P = .044$) were independently associated with facial nerve sacrifice.

Conclusion. Patients with regionally metastatic CSCC to the parotid gland frequently require sacrifice of all or a component of the facial nerve despite normal preoperative function. The likelihood of nerve sacrifice is highest for tumors with PNI and metastatic disease within the body of the parotid.

Keywords

cutaneous squamous cell carcinoma, facial nerve, metastasis, parotidectomy

Received September 17, 2020; accepted December 8, 2020.

Nonmelanoma skin cancer is the most commonly diagnosed malignancy in the United States, with cutaneous squamous cell carcinoma (CSCC) representing about 20% of those cases.¹ It is estimated that there are 700,000 patients diagnosed with CSCC each year in the United States, and the incidence has been increasing worldwide.^{2,3} Most tumors are found within the sun-exposed areas of the head and neck.

Most CSCCs require only local treatment, but a subset of patients present with regionally metastatic disease. Although the overall incidence of regional metastasis is reported to be as low as 5% or less, certain tumor characteristics are associated with a greater risk of metastasis.⁴ These include high-risk tumor location, greater diameter, increased depth of invasion, poor histologic grade, lymphovascular invasion (LVI), perineural invasion (PNI), and recurrent tumor.^{5–8} The parotid lymph nodes are the most common first echelon site of metastatic spread for CSCC of the head and neck.⁹

Metastatic involvement of lymph nodes within the parotid gland poses a therapeutic challenge. Surgical resection via comprehensive parotidectomy is recommended with the goals of complete removal of tumor and preservation of nerve function. However, the involved nodal disease is often in close proximity or directly involving the facial nerve, and nerve sacrifice is sometimes necessary to achieve microscopic or gross total resection. This can be difficult to predict in the setting of normal preoperative facial nerve function, and there are limited data on what factors are associated with greater

¹Department of Otolaryngology–Head and Neck Surgery, Indiana University, Indianapolis, Indiana, USA

²Department of Otolaryngology–Head and Neck Surgery, University of California–Davis, Sacramento, California, USA

This article was presented at AAO-HNS 2019 Annual Meeting & OTO Experience; September 16, 2019; New Orleans, Louisiana.

Corresponding Author:

Jessica Yesensky, MD, Department of Otolaryngology–Head and Neck Surgery, Indiana University, 1130 W Michigan Street, FH 400, Indianapolis, IN 46202, USA.

Email: jessicayesensky@gmail.com



risk of nerve sacrifice. In addition, philosophies differ between surgeons on when to preserve the nerve in the setting of close or positive margins.⁹

Our objective was to analyze the incidence of facial nerve sacrifice during parotidectomy for metastatic CSCC of the head and neck and to determine what tumor characteristics are associated with a higher risk of sacrifice.

Materials and Methods

We conducted a retrospective chart review of patients with CSCC treated at University of California–Davis. We received institutional review board approval from the UC Davis Comprehensive Cancer Center Scientific Review Committee to collect patient data by querying the electronic medical records of patients with biopsy-proven CSCC of the head and neck who were treated in the otolaryngology department between January 2001 and December 2018. The study population was composed of patients with resectable CSCC of the head and neck who underwent parotidectomy as part of their surgical treatment. We included patients who had pathologically proven metastatic disease to the parotid gland that was distinct from their concurrent or historical primary. This included patient with synchronous, historical, and unknown primary tumors. We excluded patients with distant metastatic disease and those with any preoperative facial nerve dysfunction. In our practice, facial nerve sacrifice was performed only when there was gross evidence of direct invasion onto or around the facial nerve. Close (<1 mm) but microscopically negative margins were generally tolerated if required to save facial nerve branches.

Clinical and pathologic factors were identified and recorded, including age at diagnosis, sex, primary vs recurrent tumor, primary tumor location, American Joint Committee on Cancer (AJCC) eighth edition pathologic T stage, histologic grade, LVI, PNI, both clinical and pathologic nodal status, metastatic nodal size, and extracapsular spread (ECS). Primary tumor location was categorized as “high risk” or “low risk” based on National Comprehensive Cancer Network (NCCN) criteria.¹⁰ Metastatic nodal size was grouped into those less than or equal to 3 cm and those greater than 3 cm, consistent with AJCC thresholds for pathologic nodal staging. Histologic grade was recorded as either poor or moderately to well differentiated. We also identified extent of parotidectomy performed (superficial, total, or radical) and location of metastasis in the parotid (body or tail).

Statistical analyses were performed with SPSS (SPSS, Inc). Descriptive statistics were computed for clinical and demographic data. The significance of univariate associations between patient and tumor characteristics, including recurrent tumor, location of nodal metastasis within the parotid gland, nodal size, ECS, LVI, PNI, and histologic grade, with facial nerve sacrifice was assessed via χ^2 analysis. A multivariate logistical regression was used to determine factors independently associated with nerve sacrifice. Statistical significance was defined as a *P* value less than .05.

Table 1. Patient Characteristics (N = 53).

Factor	No. (%)
Age, y	
≤75	23 (43%)
>75	30 (56.6%)
Sex	
Male	52 (98)
Female	1 (2)
Location in parotid gland	
Tail	23 (43.4)
Body	27 (50.9)
Type of parotidectomy	
Superficial	29 (54.7)
Total or radical	24 (45.3)
Concurrent neck dissection	47 (88.7)
Facial nerve sacrifice	
Division/branch	14 (26.5)
Total	7 (13.2)

Results

A total of 259 patients with advanced CSCC were identified. Of those, we identified 53 patients with both nodal disease in the parotid and normal preoperative facial nerve function. These results are summarized in **Table 1**. We had complete data on the primary tumor in 46 of the 53 patients. The mean (SD) age of the patients analyzed was 75 (4.1) years, with the large majority being male (98.1%). Most patients (83.0%) were presenting with a recurrence from a previously treated CSCC. Despite patients having normal preoperative facial nerve function, 27% required sacrifice of a branch of the facial nerve and an additional 13% required total nerve sacrifice to achieve a negative margin resection. These results are summarized in **Table 2**. The mean parotid node diameter was 3 cm, and 85% demonstrated ECS, which is reflected in the high proportion of patients with advanced nodal stage according to the AJCC eighth edition. Twenty-two patients (41.5%) had primary tumors with PNI, and 18 (34%) tumors had poorly differentiated histologic grade.

On univariate analysis (**Table 3**), tumors located in the body of the parotid gland were more likely to require facial nerve sacrifice when compared to tumors in the tail of the gland (*P* = .035). Tumors with PNI (*P* = .015) and ECS (*P* = .013) were also more likely to require facial nerve sacrifice than those without. On multivariate analysis (**Table 4**), tumor location in the parotid body (odds ratio [OR], 6.6; *P* = .044) and tumors with PNI (OR, 9.11; *P* = .041) were independently associated with facial nerve sacrifice.

Discussion

CSCC is the second most common type of nonmelanoma skin cancer and is increasing in incidence worldwide. The rate of metastasis remains low, but tumors with metastatic spread

Table 2. Tumor Characteristics.

Factor	No. (%)
P nodal staging ^a	
NI	4 (7.5)
N2a	20 (37.7)
N2b	1 (1.9)
N3b	27 (50.9)
Node diameter	
≤3 cm	29 (54.9%)
>3 cm	24 (45.3%)
LVI	10 (18.9)
PNI	22 (41.5)
ECS	45 (84.9)
Pathologic differentiation	
Well or moderate	25 (47.2)
Poor	18 (34)

Abbreviations: ECS, extracapsular spread; LVI, lymphovascular invasion; PNI, perineural invasion.

^aBased on American Joint Committee on Cancer eighth edition.

Table 3. Univariate Association of Factors With Nerve Sacrifice.^a

Factor	Yes, No. (%)	No, No. (%)	P value
Recurrent			
Yes	19 (43.2)	25 (56.8)	.10
No	1 (12.5)	7 (87.5)	
Location in parotid gland			
Tail	6 (26.1)	17 (73.8)	.035
Body	15 (55.6)	12 (44.4)	
Node diameter			
≤3 cm	9 (31)	20 (69)	.160
>3 cm	12 (51)	12 (50)	
LVI			
Yes	5 (50)	5 (50)	.49
No	16 (38.1)	26 (61.9)	
PNI			
Yes	13 (59.1)	9 (40.9)	.015
No	8 (25.8)	23 (74.2)	
ECS			
Yes	21 (46.7)	24 (53.5)	.013
No	0 (0)	8 (100)	
Pathologic differentiation			
Well or moderate	12 (48)	13 (52)	.563
Poor	7 (38.9)	11 (61.1)	

Abbreviations: ECS, extracapsular spread; LVI, lymphovascular invasion; PNI, perineural invasion.

^aBold indicates statistical significance ($P < .05$).

display more aggressive behavior, higher rates of recurrence, and worse overall prognosis.^{6,11} The most common site of metastatic spread from CSCC of the head and neck is the intraparotid lymph nodes.

Table 4. Factors Associated With Nerve Sacrifice: Multivariate Logistical Regression.^a

Factor	OR	P value
Recurrence	10.6	.089
Location in parotid body	6.6	.044
Node diameter >3 cm	0.46	.39
LVI	1.31	.79
PNI	9.11	.041
Poor differentiation	0.76	.73

Abbreviations: LVI, lymphovascular invasion; OR, odds ratio; PNI, perineural invasion.

^aBold indicates statistical significance ($P < .05$).

Surgical resection of parotid metastases presents a unique challenge due to the close proximity of the intraparotid lymph nodes to the branches of the facial nerve. Abutment of involved lymph nodes to the facial nerve or ECS into the parotid parenchyma can necessitate sacrifice of all or branches of the nerve to achieve complete resection. In patients with intact preoperative nerve function, it can be difficult to predict those patients who will require sacrifice based on clinical exam and radiographic imaging alone. There have been no studies to date evaluating tumor characteristics associated with facial nerve sacrifice, and we sought to identify those features.

We found that despite normal preoperative facial nerve function, parotid metastasis in CSCC carries significant risk of facial nerve sacrifice. In our cohort, 27% of patients required resection of at least 1 branch or division, and an additional 13% required total nerve resection. Other studies have cited similar rates of partial or total nerve sacrifice (30%-40%) for CSCC with parotid metastasis.^{9,11,12}

There are differing philosophies regarding nerve sacrifice in the setting of close margins to the nerve. Oncologic surgical doctrine would suggest a wide margin of normal tissue, as positive margins in CSCC have been associated with local recurrence.¹³ Tolerating a close margin in the interest of nerve preservation has been advocated for when relying on adjuvant radiation for eradication of residual, microscopic disease. Iyer et al¹⁴ reported no decline in local control or survival in patients in whom a positive margin was tolerated to preserve facial nerve function when patients were treated with adjuvant radiation. In large studies, the overall efficacy of postoperative radiation has been associated with improved outcomes in CSCC patients with high-risk features such as nodal disease or PNI.^{8,15} More data are necessary to determine the appropriate extent of surgery in patients with metastatic CSCC to the parotid.

Extracapsular extension into the parenchymal tissue makes achieving negative margins especially difficult. There was a remarkably high rate of ECS (85%) observed in our patients. We found that facial nerve sacrifice was required only in patients with ECS, as tumor was consequently invading the surrounding gland parenchyma and onto or around the facial

nerve. Prior studies have also reported a high rate of ECS (70%) in metastatic disease to the parotid lymph nodes.¹³ The rate of ECS observed within parotid lymph nodes is higher than that typically observed for metastatic disease to cervical lymph nodes in both mucosal and cutaneous SCC (50%-60%).¹⁶⁻¹⁸ The pathophysiological mechanisms driving this aggressive pattern of spread within the parotid as compared to cervical nodes remain unclear.

We found that metastasis within the parotid body vs the tail of the gland was an independent predictor of facial nerve sacrifice (OR, 9.1; $P = .044$). In our cohort, half of the patients had lymph node metastasis in the body of the gland. The body represents the majority of the gland parenchyma that the main trunk and divisions course through, so this is not altogether a surprising finding.

Our study also found that PNI identified in the primary lesion was independently associated with facial nerve sacrifice (OR, 6.6; $P = .041$). PNI is a well-recognized high-risk feature in CSCC and has been associated with local recurrence and nodal metastasis.^{19,20} Clinical symptoms of pain, numbness, or tingling can be evidence of perineural spread identified preoperatively. However, the majority of PNI is detected on histopathologic examination. Diagnostic biopsies of the primary tumor could be used to distinguish PNI and other high-risk features, help stratify the tumor preoperatively, and aid in treatment planning.

The results of our study are helpful for preoperative surgical planning in terms of predicting the likelihood of facial nerve sacrifice. Primary tumors with known PNI on diagnostic biopsy or preoperative imaging suggestive of extracapsular extension into the parotid parenchyma provide information for improved counseling on expected outcomes. If nerve sacrifice is anticipated, the surgeon can plan for adjunctive procedures such as nerve reconstruction, reanimation techniques, and eyelid augmentation.

Our study suffers from the intrinsic limitations of any single-institution, retrospective review, including potential errors in data acquisition from chart review. Many of our patients had resection of a historic primary lesion by an outside provider, and as such, we were unable to capture complete data on all original tumors. Our sample size was also limited given this unique cohort of patients, and we may be underpowered to detect association of other tumor factors with the incidence of facial nerve sacrifice. Despite these limitations, this is the first study to date evaluating factors associated with nerve sacrifice in metastatic CSCC and offers a novel set of data that can help inform head and neck surgeons.

Conclusion

Metastatic CSCC to the parotid gland frequently presents with ECS, and a high proportion of patients ultimately require sacrifice of 1 or more facial nerve branches. The likelihood of nerve sacrifice is highest in patients with nodal disease within the body of the parotid gland and in tumors with PNI. These findings can inform head and neck surgeons as they plan for parotidectomy in patients with regionally metastatic CSCC.

Author Contributions

Jessica Yesensky, design, analysis, drafting manuscript, presentation; **Roberto N. Solis**, analysis, drafting and editing manuscript; **Arnaud Bewley**, design, analysis, drafting manuscript.

Disclosures

Competing interests: None.

Sponsorships: None.

Funding source: None.

References

1. Alam M, Ratner D. Cutaneous squamous-cell carcinoma. *N Engl J Med*. 2001;344:975-983.
2. Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. *Arch Dermatol*. 2010;146:283-287.
3. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. *Br J Dermatol*. 2012;166:1069-1080.
4. Joseph MG, Zulueta WP, Kennedy PJ. Squamous cell carcinoma of the skin: the incidence of metastases and their outcome. *Aust NZ J Surg*. 1991;62:697-701.
5. Mooney CP, Martin RCW, Dirven R, et al. Sentinel node biopsy in 105 high-risk cutaneous SCCs of the head and neck: results of a multicenter prospective study. *Ann Surg Oncol*. 2019;26(13):4481-4488.
6. Moore BA, Weber RS, Prieto V, et al. Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. *Laryngoscope*. 2005;115:1561-1567.
7. Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip: implications for treatment modality selection. *J Am Acad Dermatol*. 1992;26:976-990.
8. Harris BN, Bayoumi A, Rao S, et al. Factors associated with recurrence and regional adenopathy for head and neck cutaneous squamous cell carcinoma. *Otolaryngol Head Neck Surg*. 2017;156(5):863-869.
9. O'Brien CJ, McNeil EB, McMahon JD, et al. Significance of clinical stage, extent of surgery, and pathologic findings in metastatic cutaneous squamous carcinoma of the parotid gland. *Head Neck*. 2002;24(5):417-422.
10. National Comprehensive Cancer Network. Cutaneous squamous cell carcinoma (version 1.2020). Accessed October 2019. https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf
11. Sweeny L, Zimmerman T, Carroll WR, et al. Head and neck cutaneous squamous cell carcinoma requiring parotidectomy: prognostic indicators and treatment selection. *Otolaryngol Head Neck Surg*. 2014;150(4):610-617.
12. Hong TS, Kriesel KJ, Hartig GK, et al. Parotid area lymph node metastases from cutaneous squamous cell carcinoma: implications for diagnosis, treatment, and prognosis. *Head Neck*. 2005;27(10):851-856.
13. Khurana VG, Mentis DH, O'Brien CJ, et al. Parotid and neck metastases from cutaneous squamous cell carcinoma of the head and neck. *Am J Surg*. 1995;170:446-450.

14. Iyer NG, Clark JR, Murali R, et al. Outcomes following parotidectomy for metastatic squamous cell carcinoma with microscopic residual disease: implications for facial nerve preservation. *Head Neck*. 2009;31(1):21-27.
15. Veness MJ, Morgan GJ, Palme CE, et al. Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice. *Laryngoscope*. 2005;115(5):870-875.
16. Bernier J, Dommange C, Ozsahin M, et al. European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. *N Engl J Med*. 2004;350(19):1945-1952.
17. Matsumoto F, Mori T, Matsumura S, et al. Prognostic significance of surgical extranodal extension in head and neck squamous cell carcinoma patients. *Jpn J Clin Oncol*. 2017;47(8):699-704.
18. Maxwell JH, Ferris RL, Gooding W, et al. Extracapsular spread in head and neck carcinoma: impact of site and human papillomavirus status. *Cancer*. 2013;119(18):3302-3308.
19. Harris BN, Bayoumi A, Rao S, et al. Factors associated with recurrence and regional adenopathy for head and neck cutaneous squamous cell carcinoma. *Otolaryngol Head Neck Surg*. 2017;156(5):863-869.
20. Karia PS, Morgan FC, Ruiz ES, et al. Clinical and incidental perineural invasion of cutaneous squamous cell carcinoma: a systematic review and pooled analysis of outcomes data. *JAMA Dermatol*. 2017;153(8):781-788.